Alkem Laboratories has launched semaglutide injection in India under the brand names Semasize, Obesema and Hepaglide. Semaglutide is administered as a subcutaneous injection, once weekly.
The company has launched its semaglutide pre-filled disposable injection pen at a price starting Rs 1,800 for a month’s dosage, which translates into a weekly cost of Rs 450.
Through an affordable pricing, Alkem aims to lower barriers to initiation and expand access to this therapy in India. Alkem has received approval from the Drug Controller General of India (DCGI) for manufacturing and marketing semaglutide for type 2 diabetes mellitus and chronic weight management as an adjunct to diet and exercise, subsequent to a review of its Phase 3 clinical trials conducted in India. Semaglutide is a prescription product and should be taken under appropriate medical supervision.
Apart from disposable pen, Alkem is offering reusable injection pen for semaglutide administration for higher maintenance doses. The reusable pen enables patients to replace only the medication cartridge rather than purchasing a new disposable pen each time, thereby reducing cost and helping better patient adherence to treatment.
Alkem Laboratories is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: